Pilgrim raises $25M to build America's first biodefense biology brand with its Argus airborne pathogen sensor

Pilgrim closes $25M to build airborne pathogen detection at scale

Pilgrim has closed a $25 million round to scale Argus, its portable airborne pathogen sensor, and what founder Jake Adler describes as America's first dedicated biology brand for defense.

The core problem Adler identifies is infrastructure age. The Pentagon shut down four months ago due to a false anthrax alert, and the current timeline to detect an airborne biological threat runs to roughly a week — meaning, as Adler puts it, a pandemic typically shows up in newspaper headlines before a sensor catches it. The existing toolkit is either manual, hyper-personalized to individuals, or built around contact tracing workflows that COVID-era thinking made familiar but didn't meaningfully improve.

“We closed the $25,000,000 round to build America's first biology brand... The current timeline to even detect a threat in the air is like a week. And that means by the time you find out about a pandemic, it's typically in the newspaper before one of our sensors are even picking up on it.”

Argus

Argus is a tripod-mounted, portable unit designed to monitor the ambient air passively — no breath samples, no individual testing, no lengthening of a TSA line. Adler's framing is "Shazam for the air": continuous environmental surveillance that detects and characterizes airborne pathogens autonomously rather than flagging individuals after exposure has already spread.

The form factor is deliberate. Airborne transmission is the primary vector for viral spread between populations, and Pilgrim wants the system visible enough in airport environments to function as a deterrent as well as a sensor. Adler is clear that detection alone isn't enough — the system has to identify and characterize the threat, not just raise an alarm, because a positive signal without actionable characterization leaves operators with nowhere to go.

Longer platform bet

Argus is Pilgrim's wedge, but Adler's stated ambition is broader: a platform that deploys across wastewater, clinical, and other environmental media. The common thread is accelerating the path from academic or lab-stage biotechnology into the hands of warfighters and civilian infrastructure, which Adler argues has been stuck for roughly two decades. Drone and wheeled deployments of the Argus sensor are on the table as the platform matures.

The validation process Adler describes — where suppliers phone to confirm government affiliation before shipping biological agents for testing — hints at how thin the commercial and regulatory infrastructure around biodefense actually is, which is both the market gap Pilgrim is betting on and the reason building here has taken this long.